论文部分内容阅读
目的通过观察顽固性肝硬化腹水病人放腹水后应用低分子右旋糖苷(dextran-40)治疗的疗效,试图寻找廉价而有效的治疗方法。方法89例顽固性肝硬化腹水病人一次尽可能完全放腹水并随机分为两组。第1组输注人体白蛋白,第2组输注同等胶体渗透压的低分子右旋糖苷。比较两组出院后并发症的发生率、大量腹水的复发率已及生存率。结果低分子右旋糖苷(dextran-40)治疗组,病人平均每年并发症的发生率、大量腹水的复发率以及5年生存率与输注人体白蛋白组无显著差异(P>0.05)。结论顽固性肝硬化腹水病人完全放腹水后,输注低分子右旋糖苷可以安全地替代人体白蛋白。
Objective To find a cheap and effective treatment by observing the curative effect of dextran-40 treatment after ascites in patients with refractory cirrhosis of the liver. Methods A total of 89 patients with refractory cirrhosis and ascites were ascites as completely as possible and were randomly divided into two groups. Group 1 infusion of human albumin, group 2 infusion of the same colloid osmotic pressure of low molecular weight dextran. Comparing the incidence of complications after discharge, a large number of ascites recurrence rate and survival rate. Results In the dextran-40 treatment group, the average annual complication rate, the recurrence rate of large amount of ascites and the 5-year survival rate were not significantly different from those of the human albumin infusion group (P> 0.05). Conclusion Intraperitoneal refractory cirrhosis ascites patients completely ascites, infusion of low molecular weight dextran safely replaced by human albumin.